- Clinical Center
- Medical Oncology
- Gynecologic Oncology
- Traditional Chinese Medicine/Integrative Oncology
- Radiation Oncology
- Medical Laboratory
Add: 283 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, P.R. China
The Future Tendency of Lung Cancer Treatment- Individualized Treatment
Lung cancer is the tumor with the highest morbidity in the world now, which causes damage severely to human health. At present, for different patients with the same histologic types of lung cancer, the treatment is usually using the same medicine and standard dose, but the fact is, different patients have great differences in the therapeutic effect and adverse reaction. It is not enough for the current clinical used traditional detection index to provide enough information for clinicaldoctors to precisely predict the prognosis of complicated situations for cancer patients. With the dramatic breakthrough of pharmacogenomics/pharmacogenomics and tumor molecular biology in the chemotherapy drugs and Targeted drugs (Targeted Medicine) mechanism, and choosing the appropriate drugs for individualized treatment by relative gene detection, predicting the curative effect of drugs, have become a reasonable choice to improve therapeutic efficacy, and reduce futile treatment.
To realize the "individualization treatment", the detection of gene level is necessary that make the patients access to the most effective treatment, and also avoid the side effects of drugs to the maximum. Whether technology principle and equipment, or quality standard, this technique of gene sequencing has developed for decades, and all has reached a high standardization in the world. At present, with the continuous breakthrough of new sequencing technologies and analytical methods, the cost of the whole genome sequence analysis has been greatly reduced, genetic sequencing has become a routine testing technology that can be applied in clinical. With this new diagnosis technology, doctors can adjust prescription for the patients before the drug use, and choose the appropriate drugs, which can greatly reduce unnecessary pain and finicial burden for patients, and achieve real "tailored" individualized medication.
Our department has extended a wide range of cooperation with the departments of pathology, clinical laboratory and central laboratory, we develop tumor individualized drug use genetic testing for patients with lung cancer. According to characteristics of pharmacogenetics and pharmacogenomics, we select the drugs whose specificity and targeting are the best, and actively develop lung cancerindividualized treatment on the basis of the technology of gene sequencing. Individualized treatment can help patients choose the appropriate chemotherapeutic drugs or targeted drugs, improve thespecific target of treatments, and extend the life expectancy of patients to the maximum; For instance, according to genes test results such as EGFR ,ALK and ROS1 genes etc, use targeted drugs, for EGFR mutation positive patients, use the targeted drugs Gefitinib (Yi Rui sand), erlotinib (tarceva), Icontinib(kay) etc, whose efficient is more than 70%, ALK, ROS1 positive patients, accept azole(Crizotinib) treatment, efficient about 70%. Because of targeted drugs above having the characteristics that high selectively kill cancer cells without killing or having only very little damage to normal cells, the side effects are relatively small, it effectively improve the patient's life quality and therapeutic efficacy. However, precisely because targeted therapy is designed to attack specific target molecular, so it is necessary to detect if patients have the corresponding target before medication, so as to play its efficacy.
Large-scale randomized compared clinical trial results on the basis of evidence-based medicine only can reflect an average effect and probability of the specific people; however patients are different individuals with various characteristics in clinical practice, therefore, only tumor individualized treatment is on the basis of evidence-based medicine, it can benefit patients most. Furthermore, we should take patients＇bearing capacity into consideration on various aspects in physiology, psychology, economy and soon, and ensure it can benefit patients to the maximimum, which is the basic principles of tumor individualized comprehensive treatments.
Thoracic Medicine Department 2 Hou Qiong